

THE EFFECT OF ANTIPROSTAGLANDINS ON CIRCULATING  
PLATELET AGGREGATES IN IUCDs USERS  
WITH MENORRHAGIA

THESIS

Submitted for Partial Fulfilment of

Master Degree in

Obstetrics and Gynaecology

By

AMIR HABIB-AFFENDI BOTROS

M.B.B.Ch.

1982

----



18707-



SUPERVISORS

PROF.Dr.ALY MAREI MAKHLOUF  
Prof.OF OBSTETRICS AND GYNAECOLOGY  
AIN SHAMS UNIVERSITY

Dr.NABEGH EL MAHALAWY  
LECTURER OF OBSTETRICS AND GYNAECOLOGY  
AIN SHAMS UNIVERSITY

Dr.FEKRY GOUBRAN  
LECTURER OF CLINICAL PATHOLOGY  
SUEZ CANAL UNIVERSITY

((((((((  
(((((  
(((  
((  
(

أستاذ  
الطبي  
الطبي  
الطبي  
الطبي



## CONTENTS

	Page
I. Introduction .....	1
II. Aim of the work .....	3
III. Review of literature .....	5
- Uterine bleeding with IUDs .....	5
- Platelet functions .....	30
- In vitro tests for measurement of platelet aggregation .....	42
- Circulations platelet aggregates and diseases .....	44
- In vivo tests for measurement of platelet aggregates .....	46
- Prostaglandins and platelets .....	49
- Effect of antiprostaglandins on platelet aggregation .....	63
IV. Experimental work .....	66
- Selection of cases .....	66
- Patient dosing .....	68
- Methodology .....	69
- Results .....	71
V. Discussion .....	77
VI. Summary .....	96
VII. References .....	99
VIII. Arabic Summary .....	133

### ACKNOWLEDGEMENT

To Professor Dr. ALY MAREI MAKHLOUF, Professor of Obstetrics and Gynaecology, Ain Shams University, I wish to express my sincer gratitude for his continous, cardinal encourgment, supervision and valuable advices which were essential for this work to be finally achived.

I am sincerely grateful to Dr. NABEGH EL MAHALAWY , Lecturer of Obstetrics and Gynaecology, Ain Shams University for his great help, advice, encouragment and supervision of the whole work.

To Dr. FEKRY GOUBERAN, Lecturer of Clinical Pathology, Suez Canal University, I am deeply indebted for his great help, enormous and continous assistance which constiute the backbone of this work. He supervised the whole work, closely revised the literature, supervised all the laboratory procedures, evalusted the results and supplied me with many refrences for this work.

I wish also to express my greatful thanks to Prof. Dr. M.N.EL MAKHAZANGY, Ass. Prof. of Obstetrics and gynaecology, Ain Shams University, for although he was not

a supervisor for this thesis, he revised and followed up the whole work, especially in the practical part in relation to another two related studies.

Thanks to the members of parke davis pharmaceutical company, represented in Dr. W.I. WASIF, Medical Director, Middle East, for supplementation of mefenamic acid capsules (Ponstan) and the placebo which were used in this study.

My thanks are also sincerely extended to all the members of the Family Planning Center of Ain Shams University for their valuable help.

I am very grateful to every one who have helped me in this work and specially to our patients who had tollerated the work.

# INTRODUCTION

## INTRODUCTION

-----

For the last twenty years, intrauterine contraceptive devices have been used with varying success in clinical practice and in the family planning programs through out the world.

In theory the IUD is close to an ideal contraceptive method. Although it requires a clinical procedure, it is a physician dependant not related to coitus, usually requires a single insertion and rarely causes systemic hazards.

It provides a long-term protection against pregnancy, easily reversed, and in the same time is relatively inexpensive. The ideal IUD would be placed into the uterus when a woman decides she no longer wants to conceive and it could remain there through out her life, or until hysterectomy, or until the woman desires renewed fertility (Tietz 1970).<sup>223</sup>

In practice, the first generation of IUDs gave problems of expulsion, accidental pregnancy, perforation, infection, pain and bleeding that made them less than ideal for many women.



Bleeding disturbances are the major drawbacks in using IUDs, and considered to be among the main reasons for discontinuing this method of contraception (68,164,199)

This bleeding which takes the form of intermenstrual spotting and /or menorrhagia is mostly seen during the first few days and month and tends to improve later.<sup>169</sup>

# AIM OF THE WORK

## AIM OF THE WORK

Intra-uterine devices are becoming increasingly used method of contraception throughout the world for the multiple advantages, rendering it preferable to other methods and sometimes, the method of choice for some women.

In spite of this, there are still some drawbacks rendering IUDs less than ideal.

Researches are going on to give the proper solution to these problems.

One of the main drawbacks of IUDs is the bleeding disturbances in the form of menorrhagia and/or metrorrhagia.

Many trials with varying success have been done in this field.

The medicated IUDs, loaded with copper or progesterone have been developed.

Systemic treatment in the form of antiprostaglandins antifibrinolytics, hormonal and other drugs have been used with varying success. One of these drugs is mefenamic acid, which has been used with success in treatment of excessive bleeding with IUDs. The mechanism by which this antiprostaglandin, mefenamic acid, reduces excessive

uterine bleeding associating IUDs is not exactly well known. One of the postulated mechanisms is that it may increase platelet aggregation.

For this reason, in vivo circulating platelet aggregates were measured in an attempt to provide an accurate approximation of the behaviour of platelets in their natural situation in response to oral administration of antiprostaglandins.

# **REVIEW OF LITERATURE**

## UTERINE BLEEDING WITH IUDs

The term uterine bleeding is used to cover every deviation from the normal menstrual pattern.<sup>198</sup>

Normal menstrual blood loss ranges between 30-45 ml per menses.<sup>72</sup>

The menstrual period is considered to be complete when bleeding has ceased for at least two days.

### TYPES OF BLEEDING WITH IUDs:

- I . Increased menstrual blood loss at cyclical periods ( MBL )
- II . Increased duration of bleeding.
- III. Intermenstrual bleeding and spotting(IMB).

The type of device used,duration of usage,varied individual response to the same type of IUDs,cultural and social background of the women,previous pattern of menstruation and the amount of blood normally lost before inserting the IUD,nutritional status,parity,may all play avariable role to influence the frequency of bleeding and IUD removal<sup>84</sup>

#### I. Increased menstrual blood loss(MBL):

With the exception of progestational IUDs,all IUDs

lead to increase menstrual blood loss by about 50-100 % over the usual preinsertion levels.<sup>67,70,104</sup>

Larsson et al (1975)<sup>119</sup>, have reported that 159 % increase of MBL with Dalkon shield, compared to 146 % increase with lippes loop, while MBL with copper-7 was 57 % and with copper-T, it was 85 %.

Liedholm et al,<sup>121</sup> have reported that the larger non medicated IUDs are associated with a higher mean MBL than smaller copper-bearing IUDs. However, Hefnowi and co-workers (1977),<sup>87</sup> reported that the MBLs were not significantly different from women who used a lippes loop D with or without copper.

Malmquist, et al (1974),<sup>133</sup> reported that, women with documented preinsertion histories of menorrhagia have a proportionally small increase in MBL than do women with normal preinsertion MBL.

Progestrone-releasing devices in contrast to other IUDs appear to reduce the MBL volume from the pre-insertion level<sup>138</sup>.

Guillebaud et al (1976)<sup>68</sup>, have studied the relation between parity and the increased MBL with IUDs. They